288 related articles for article (PubMed ID: 16815688)
1. Efficacy of cefminox compared with amoxicillin/clavulanic acid as a single dose for the prevention of intra-abdominal sepsis in mice intraperitoneally infected with different strains of Escherichia coli and one strain of Bacteroides fragilis.
Huelves L; Gracia M; Del Prado G; Rodríguez-Cerrato V; Martínez-Marín C; Ponte C; Soriano F; Coronel P; Gimeno M; Blanco J
Int J Antimicrob Agents; 2006 Aug; 28(2):151-3. PubMed ID: 16815688
[No Abstract] [Full Text] [Related]
2. Effect of amoxycillin/clavulanic acid (augmentin) against polymicrobial Bacteroides fragilis/Escherichia coli infections in the mouse.
Beale AS; Gisby J; Sutherland R
J Chemother; 1989 Jul; 1(4 Suppl):78-9. PubMed ID: 16312312
[No Abstract] [Full Text] [Related]
3. Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli.
Schaumann R; Blatz R; Beer J; Ackermann G; Rodloff AC
J Antimicrob Chemother; 2004 Feb; 53(2):318-24. PubMed ID: 14729746
[TBL] [Abstract][Full Text] [Related]
4. Effect of prophylactic antibiotics upon mixed infections with Bacteroides fragilis.
Brook I
Surg Gynecol Obstet; 1987 Dec; 165(6):491-5. PubMed ID: 3317944
[TBL] [Abstract][Full Text] [Related]
5. Development of Candida albicans and C. albicans/Escherichia coli/Bacteroides fragilis intraperitoneal abscess models with demonstration of fungus-induced bacterial translocation.
Sawyer RG; Adams RB; May AK; Rosenlof LK; Pruett TL
J Med Vet Mycol; 1995; 33(1):49-52. PubMed ID: 7650578
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy and pharmacokinetic properties of ciprofloxacin in intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.
Fu KP; Vince T; Bloom R; Gregory FJ; Hung PP
Drugs Exp Clin Res; 1987; 13(8):493-6. PubMed ID: 3322752
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice.
Thadepalli H; Chuah SK; Gollapudi S
Chemotherapy; 2004 Jun; 50(2):76-80. PubMed ID: 15211081
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of fluconazole in murine Candida albicans and bacterial C. albicans peritonitis and abscess formation.
Sawyer RG; Adams RB; Rosenlof LK; May AK; Pruett TL
J Med Vet Mycol; 1995; 33(2):131-6. PubMed ID: 7658305
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of amoxycillin/clavulanic acid in experimental Bacteroides fragilis/Escherichia coli mixed infections.
Beale AS; Gisby J; Sutherland R
J Antimicrob Chemother; 1988 Apr; 21(4):451-9. PubMed ID: 3288604
[TBL] [Abstract][Full Text] [Related]
10. In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.
Stearne LE; Gyssens IC; Goessens WH; Mouton JW; Oyen WJ; van der Meer JW; Verbrugh HA
Antimicrob Agents Chemother; 2001 May; 45(5):1394-401. PubMed ID: 11302801
[TBL] [Abstract][Full Text] [Related]
11. Comparative activity of ertapenem and piperacillin tazobactam in a murine systemic infection model with Bacteroides fragilis and Escherichia coli.
Santos KVD; Nicoli JR; Martins WA; Coutinho SC; Apolônio ACM; Diniz CG; Carvalho MAR; Farias LM
J Med Microbiol; 2007 Nov; 56(Pt 11):1576-1579. PubMed ID: 17965366
[No Abstract] [Full Text] [Related]
12. [Strain of Escherichia coli resistant to broad-spectrum cephalosporin and amoxicillin/clavulanic acid].
Martín-Pozo A; Alós JI
Rev Esp Quimioter; 2012 Sep; 25(3):222-3. PubMed ID: 22987271
[No Abstract] [Full Text] [Related]
13. In-vivo bactericidal activity of Sch 34343 in Bacteroides fragilis abscesses and in Bacteroides fragilis-Escherichia coli abscesses.
Wells CL; Arland LA; Simmons RL; Rotstein OD
J Antimicrob Chemother; 1985 Jun; 15 Suppl C():199-206. PubMed ID: 3897172
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of amoxycillin-clavulanate in an experimental model of murine pneumonia caused by AmpC-non-hyperproducing clinical isolates of Escherichia coli resistant to cefoxitin.
Docobo-Pérez F; Fernández-Cuenca F; Pachón-Ibáñez ME; Pascual A; Pichardo C; Martínez-Martínez L; Pachón J
Clin Microbiol Infect; 2008 Jun; 14(6):582-7. PubMed ID: 18294246
[TBL] [Abstract][Full Text] [Related]
15. Amoxicillin/clavulanate (Augmentin) resistant Escherichia coli in bacterial peritonitis after abdominal surgery--clinical outcome in ICU patients.
Rahnama'i MS; Wagenvoort JH; van der Linden CJ
Neth J Med; 2009 May; 67(5):173-6. PubMed ID: 19581666
[TBL] [Abstract][Full Text] [Related]
16. False amoxicillin/clavulanic acid susceptibility in Bacteroides fragilis using gradient strip tests.
Rentenaar RJ; Bovo-Heijmans B; Diggle J; Fluit AC; Wootton M
Anaerobe; 2021 Jun; 69():102358. PubMed ID: 33741507
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacies of amoxicillin-clavulanic acid and ampicillin-sulbactam against experimental Bacteroides fragilis-Escherichia coli mixed infections.
Gisby J; Beale AS
Antimicrob Agents Chemother; 1988 Dec; 32(12):1830-3. PubMed ID: 3072924
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice.
Brook I
J Infect Dis; 1989 Oct; 160(4):651-6. PubMed ID: 2677161
[TBL] [Abstract][Full Text] [Related]
19. Antibiotic penetration of experimental intra-abdominal abscesses.
Galandiuk S; Lamos J; Montgomery W; Young S; Polk HC
Am Surg; 1995 Jun; 61(6):521-5. PubMed ID: 7762902
[TBL] [Abstract][Full Text] [Related]
20. In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.
Thadepalli H; Reddy U; Chuah SK; Thadepalli F; Malilay C; Polzer RJ; Hanna N; Esfandiari A; Brown P; Gollapudi S
Antimicrob Agents Chemother; 1997 Mar; 41(3):583-6. PubMed ID: 9055997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
